22 reports

Edit completed her PhD in Cancer Immunology/ Immunotherapy at St.

  • Stroke
  • East Asia
  • United States
  • Demand
  • Forecast
  • NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE, PHARMACEUTICALS & HEALTHCARE, DEALS BY THERAPY AREA, 2012 TO YTD 2018

Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Pharmaceuticals and Healthcare No. of Deals ## ## ## ## ## ## Deal Value (US$ million) NA NA NA NA NA NA Note: Deals include all announced pharmaceuticals & h

  • Mental Health
  • Neurological Disorder
  • Pathology
  • Stroke
  • United States

The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases.

  • Neurology
  • Stroke
  • Medtronic, Inc.
  • Penumbra
  • Stryker Corporation

The study will also assess Excellent Outcome (mRS =##, NIHSS =##, and Barthel Index =##) at three months and one year as key secondary endpoints.

  • Healthcare
  • Pharmaceutical
  • Stroke
  • Japan
  • Athersys, Inc.

The company offers discovery services in synthetic chemistry, pharmacology, analytics, immunology, neurology and biochemistry.

  • Stroke
  • Therapy
  • United States
  • Product Initiative
  • Synovo GmbH

Each unit consists of one common share and one half of one share purchase warrant.

  • Stroke
  • Therapy
  • United States
  • Corporate Finance
  • DiaMedica Inc.
  • RECOMBINANT PROTEIN TO INHIBIT CXCL FOR PANCREATITIS, CARDIOVASCULAR AND IMMUNOLOGY - DRUG PROFILE
  • STROKE

CENTER OF MOLECULAR IMMUNOLOGY (CIM) IS INVESTIGATING EPOETIN ALFA (NEUROEPO).

  • Pathology
  • Pharmaceutical
  • Stroke
  • Therapy
  • Athersys, Inc.
  • RECOMBINANT PROTEIN TO INHIBIT CXCL FOR PANCREATITIS, CARDIOVASCULAR AND IMMUNOLOGY - DRUG PROFILE
  • PIPELINE BY UNIVERSITIES/INSTITUTES

It provides pharmaceuticals in cancer, neuroscience, infection, immunology, ophthalmology, cardiovascular and metabolism, hematology, neurology and respiratory disease areas.

  • Pharmaceutical
  • Stroke
  • Therapy
  • Company
  • Product Initiative

Prior to joining NYU in 1995, he was a Professor of Microbiology and Immunology at the University of California, San Francisco.

  • Cardiovascular Disease
  • Clinical Trial
  • Stroke
  • United States
  • Pfizer Inc.

Similarly, the universities portfolio in Preclinical and Discovery stages comprises ## and ## molecules, respectively.

  • Dementia
  • Stroke
  • Therapy
  • United States
  • Product Initiative

One unit is defined as one system. ##. ##T MRI Systems This market segment includes MRI Systems with ## Tesla in field strength.

  • Biopsy
  • Diagnostic Imaging
  • Stroke
  • United States
  • Company
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Clinical Trial
  • Drug Development
  • Stroke
  • World
  • Otsuka Pharmaceutical Co., Ltd.

One unit is defined as one system.

  • Diagnostic Imaging
  • Hospital
  • Stroke
  • United States
  • Company

One unit refers to one embolization coil.

  • Pharmaceutical
  • Prosthesis
  • Stroke
  • United States
  • Company

One unit refers to one electromyograph.

  • Drug Development
  • Healthcare
  • Stroke
  • United States
  • Company
  • MULTISTEM - DRUG PROFILE

The company offers services in the areas of cell biology, immunology and medicinal chemistry.

  • Cell Therapy
  • Stroke
  • United States
  • Product Initiative
  • Athersys, Inc.

One unit refers to one embolization coil.

  • Clinical Trial
  • Hospital
  • Interventional Cardiology Device
  • Stroke
  • MicroVention, Inc.

THR-## is a peptide derived from plasminogen activator inhibitor-## (PAI-##).

  • Pharmaceutical
  • Stroke
  • Therapy
  • United States
  • Product Initiative

THR-## BINDS AT ONE OF THE PAI-## DOCKING SITES ON TPA THAT LEAVES TPA' S CATALYTIC ACTIVITY INTACT.

  • Pharmaceutical
  • Stroke
  • Therapy
  • Product Initiative
  • AB Science SA

MP-## is a poly ADP ribose polymerase ## (PARP-##) inhibitor.

  • Research And Development
  • Stroke
  • United States
  • Company Operations
  • AB Science SA

PATIENTS WERE RANDOMIZED (##:##:##) TO RECEIVE ARRY-##, PLACEBO OR OXYCODONE ER WHILE CONTINUING THEIR USE OF NSAIDS.

  • Analgesic
  • Hospital
  • Stroke
  • United States
  • Product Initiative